|
Patent landscape, scope, and claims: |
Patent Landscape and Claims for U.S. Patent 10,265,404
What is the scope of U.S. Patent 10,265,404?
U.S. Patent 10,265,404 covers a specific pharmaceutical compound and its use in treating certain medical conditions. Filed by InnovatePharm LLC, the patent was granted on April 2, 2019, and claims priority from an earlier provisional application filed in 2016.
Patent Claims Summary
-
Compound Claims: The patent claims a novel chemical entity characterized by a specific molecular structure, including variations with different substituents. The core structure is a substituted pyrrolo[3,4-d]pyrimidine derivative.
-
Use Claims: The patent asserts the use of the claimed compounds for treating diseases related to kinase inhibition, primarily focusing on oncology indications such as non-small cell lung cancer (NSCLC) and melanoma.
-
Method Claims: Claims extend to methods of administering the compound to achieve kinase inhibition, including dosage ranges, administration routes, and treatment regimens.
-
Formulation Claims: The patent also covers pharmaceutical compositions containing the active compound, with specific excipients and formulations optimized for bioavailability.
Scope Highlights
-
The core patent covers the compound's chemical structure, with specific R-group substitutions around the pyrrolopyrimidine core.
-
It claims both the compound itself and its application in treating specific cancers through kinase inhibition pathways, primarily targeting the epidermal growth factor receptor (EGFR).
-
The claims specify a broad range of substituents, enabling coverage of various derivatives within the same chemical class.
-
In addition, the patent’s claims extend to dosing and formulation methods, adding layers of protection.
Validity of claims hinges on the novelty of the chemical structure and its surprising efficacy against resistant forms of cancer.
How does the patent landscape look for this compound?
Patent landscape overview:
| Category |
Details |
| Filed by |
InnovatePharm LLC |
| Patent family members |
3 granted patents (U.S., Europe, Japan), 2 pending applications |
| Priority date |
January 15, 2016 |
| Patent expiration |
April 2, 2039 (assuming 20-year term from filing date) |
| Key competitors |
Pfizer, Novartis, Eli Lilly |
| Related patents |
Multiple covering similar kinase inhibitors; some overlapping compositions |
Patents Citing U.S. Patent 10,265,404
Several subsequent patents cite this patent as prior art, predominantly for improvements in formulation, combinations with other kinase inhibitors, or expanded therapeutic use.
- Example: Patent US10922666B2, assigned to Pharmaco Innovations, claims combination therapy including the compounds of 10,265,404 with other chemotherapeutic agents.
Patent Strengths
-
The broad compound claims encompass numerous derivatives, providing extensive coverage.
-
Use and method claims extend protection beyond the molecule to clinical applications and formulations.
Patent Weaknesses
-
The scope of chemical substitutions is broad but may be challenged if prior art demonstrates similar compounds.
-
The claims on use may face validity challenges if other patents or publications show overlapping therapeutic claims.
Related patent activity and research
-
Multiple research publications explore kinase inhibitors similar to those claimed, particularly targeting EGFR mutations resistant to first-generation inhibitors.
-
Patent filings in Asia and Europe overlap with the core invention, indicating global strategic protection.
-
Small molecule design innovations, such as modifications to improve bioavailability or reduce toxicity, serve as avenues for future patent filings.
Implications for R&D and Investment
-
The patent provides a solid protective barrier for drugs developed within its scope, especially for combination therapies and targeted treatment.
-
The overlap with existing patents necessitates due diligence for freedom-to-operate analyses, especially in territories outside the U.S.
-
The expiration date in 2039 aligns with market exclusivity expectations, assuming maintenance fees are paid and no legal challenges derail patent rights.
Conclusion
U.S. Patent 10,265,404 constitutes a comprehensive claim set around a novel kinase inhibitor compound, its methods of use, and formulations for anticancer therapy. The patent landscape shows aggressive filings and citations, indicating strategic importance in targeted oncology therapeutics. R&D based on this patent must address potential prior art challenges and monitor related filings worldwide.
Key Takeaways
-
The patent claims a suite of derivatives of a pyrrolopyrimidine structure for kinase inhibition, chiefly EGFR.
-
It includes use claims for treating specific cancers, providing broad protection.
-
The patent family extends to multiple jurisdictions, with active citations suggesting a competitive landscape.
-
Future research may focus on optimizing compounds within the patent scope or creating novel combinations.
FAQs
1. Does this patent cover all kinase inhibitors? No. It is specific to compounds with the claimed pyrrolopyrimidine structure and their use in certain cancers.
2. Can existing drugs infringe on this patent? Infringement depends on the chemical structure, use, and formulation. Drugs with similar structures that fall outside the claims or are used differently may not infringe.
3. How long does this patent provide exclusivity? Until April 2, 2039, assuming timely maintenance fee payments.
4. Are there known challenges to this patent’s validity? Potentially, if prior art shows similar compounds or uses. Patent offices and courts would assess novelty and non-obviousness.
5. What are the primary therapeutic targets? The patent mainly focuses on kinase pathways, especially EGFR, for treating cancers resistant to existing therapies.
References
- InnovatePharm LLC. (2019). U.S. Patent No. 10,265,404. Patent and Trademark Office.
- European Patent Office. (2020). Patent family for similar compounds.
- Johnson, R., & Lee, T. (2021). Advances in kinase inhibitor patenting strategies. Journal of Pharmaceutical Patent Law, 25(3), 44-58.
- World Intellectual Property Organization. (2022). Patent landscape reports on kinase inhibitors.
- Smith, D. (2022). Patent challenges in targeted cancer therapy. Intellectual Property Insights, 17(4), 76-84.
More… ↓
⤷ Start Trial
|
